GlassScriptPhysician profile
William Brady Shaw
NPI 1417344011
$1,156.49
in general payments reported to CMS, 2019-2025
26 companies · $51.31 in 2025
The $51.31 reported for 2025 was less than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $265 · 2020: $221 · 2021: $347 · 2022: $256 · 2023: $15.65 · 2025: $51.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $66.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $66.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $348.80 | 2019-2023 | Ubrelvy |
| Emd Serono, INC. | $98.24 | 2020-2022 | |
| Ucb, INC. | $93.78 | 2019-2021 | |
| Merz North America, INC. | $90.47 | 2019 | |
| Allergan, INC. | $73.54 | 2021-2022 | |
| Genzyme Corporation | $65.34 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $51.31 | 2025 | Dysport |
| Eisai INC. | $30.05 | 2019-2021 | |
| Amgen INC. | $28.75 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $28.75 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.32 | 2022 | |
| Biogen, INC. | $19.25 | 2019 | |
| Acorda Therapeutics, INC | $17.98 | 2019 | |
| Livanova USA, INC. | $17.76 | 2020 | |
| Mallinckrodt Hospital Products INC. | $17.34 | 2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $17.00 | 2019 | |
| Alexion Pharmaceuticals, INC. | $16.90 | 2020 | |
| Neurocrine Biosciences, INC. | $16.31 | 2020 | |
| Upsher-Smith Laboratories LLC | $15.09 | 2021 | |
| Amneal Pharmaceuticals LLC | $13.57 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.45 | 2019 | |
| Endo Pharmaceuticals INC. | $12.29 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $12.16 | 2021 | |
| Lilly USA, LLC | $11.75 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.72 | 2021 | |
| Zyla Life Sciences, INC. | $11.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Shaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.